Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Eli Lilly and Co.

Eli Lilly and Company is unveiling its new 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, which will be available ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

The recent approval of Omvoh for Crohn's disease marks the company's entry into the inflammation market, following the approval of Ebglyss for Atopic Dermatitis. These developments demonstrate Eli ...

This article delves into the three approved assets in this class – AbbVie’s Skyrizi (risankizumab), Eli Lilly’s Omvoh (mirikizumab), and J&J’s Tremfya (guselkumab) – and explores how ...

Op maandag handhaafden analisten van Bernstein, waaronder Courtney Breen, hun positieve vooruitzichten voor aandelen van Eli ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn ...

In een recente transactie heeft Lilly Endowment Inc., een belangrijke aandeelhouder in Eli Lilly & Co. (NYSE: LLY ), een aanzienlijk deel van haar belang verkocht. De stichting deed 78.025 aandelen va ...

Eli Lilly's performance in the biopharmaceutical sector reflects its strong market position, despite facing challenges. The ...

Developed by Johnson & Johnson, guselkumab (GUS) is the first approved fully-human, dual-acting IL-23p19 subunit inhibitor that blocks IL-23 and binds to CD64, a receptor on cells that produce IL-23.